메뉴 건너뛰기




Volumn 37, Issue 7, 2014, Pages 351-359

Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells

Author keywords

adoptive immunotherapy; erbB2; gene therapy; scFv; tumor

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD3 ZETA ANTIGEN; CHIMERIC PROTEIN; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; PACLITAXEL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HYBRID PROTEIN; T LYMPHOCYTE RECEPTOR;

EID: 84906078950     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000048     Document Type: Article
Times cited : (9)

References (63)
  • 1
    • 33644777800 scopus 로고    scopus 로고
    • A trimeric anti-HER2/neu ScFv and tumor necrosis factor-Alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia
    • Huang TH, Morrison SL. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-Alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther. 2006;316:983-991
    • (2006) J Pharmacol Exp Ther , vol.316 , pp. 983-991
    • Huang, T.H.1    Morrison, S.L.2
  • 2
    • 0034638917 scopus 로고    scopus 로고
    • Overexpression of ErbB2 in cancer and ErbB2-Targeting strategies
    • Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-Targeting strategies. Oncogene. 2000;19:6115-6121
    • (2000) Oncogene , vol.19 , pp. 6115-6121
    • Yu, D.1    Hung, M.C.2
  • 3
    • 33645688204 scopus 로고    scopus 로고
    • HER2-positive circulating tumor cells indicate poor clinical outcome in stage i to III breast cancer patients
    • Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12: 1715-1720
    • (2006) Clin Cancer Res , vol.12 , pp. 1715-1720
    • Wulfing, P.1    Borchard, J.2    Buerger, H.3
  • 4
    • 0032078876 scopus 로고    scopus 로고
    • ERBB2 oncogene in human breast cancer and its clinical significance
    • Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791-808
    • (1998) Eur J Cancer , vol.34 , pp. 791-808
    • Revillion, F.1    Bonneterre, J.2    Peyrat, J.P.3
  • 5
    • 0032982818 scopus 로고    scopus 로고
    • Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
    • Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79: 1220-1226
    • (1999) Br J Cancer , vol.79 , pp. 1220-1226
    • Houston, S.J.1    Plunkett, T.A.2    Barnes, D.M.3
  • 6
    • 33750699642 scopus 로고    scopus 로고
    • A phase i study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
    • Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-6115
    • (2006) Clin Cancer Res , vol.12 , pp. 6106-6115
    • Kershaw, M.H.1    Westwood, J.A.2    Parker, L.L.3
  • 7
    • 50849123421 scopus 로고    scopus 로고
    • HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
    • Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529
    • (2008) Ann Oncol , vol.19 , pp. 1523-1529
    • Gravalos, C.1    Jimeno, A.2
  • 9
    • 84874849358 scopus 로고    scopus 로고
    • Erbb2 overexpression in uterine serous cancer: A molecular target for trastuzumab therapy
    • Elsahwi KS, Santin AD. erbB2 overexpression in uterine serous cancer: A molecular target for trastuzumab therapy. Obstet Gynecol Int. 2011;128295:5
    • (2011) Obstet Gynecol Int , vol.5 , pp. 128295
    • Elsahwi, K.S.1    Santin, A.D.2
  • 10
    • 84874928725 scopus 로고    scopus 로고
    • Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: A possible target for immunotherapy
    • Zuhur SS, Tanik C, Erol RS, et al. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: A possible target for immunotherapy. Turk Neurosurg. 2013;23:55-60
    • (2013) Turk Neurosurg , vol.23 , pp. 55-60
    • Zuhur, S.S.1    Tanik, C.2    Erol, R.S.3
  • 11
    • 23844510061 scopus 로고    scopus 로고
    • Anti-erbB-2 antibody trastuzumab in the treatment of HER2-Amplified breast cancer
    • Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-Amplified breast cancer. Invest New Drugs. 2005;23:391-409
    • (2005) Invest New Drugs , vol.23 , pp. 391-409
    • Yeon, C.H.1    Pegram, M.D.2
  • 12
    • 33748525213 scopus 로고    scopus 로고
    • Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    • Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 2006;11:857-867
    • (2006) Oncologist , vol.11 , pp. 857-867
    • Gonzalez-Angulo, A.M.1    Hortobagyi, G.N.2    Esteva, F.J.3
  • 13
    • 42149131528 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    • Osako T, Ito Y, Takahashi S, et al. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62:159-164
    • (2008) Cancer Chemother Pharmacol , vol.62 , pp. 159-164
    • Osako, T.1    Ito, Y.2    Takahashi, S.3
  • 14
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed. 2001;344:783-792
    • (2001) N Engl JMed , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 15
    • 33947165711 scopus 로고    scopus 로고
    • Phage display of chelating recombinant antibody libraries
    • Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol. 2007;44:2860-2869
    • (2007) Mol Immunol , vol.44 , pp. 2860-2869
    • Wright, M.J.1    Deonarain, M.P.2
  • 16
    • 70349342731 scopus 로고    scopus 로고
    • Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells
    • Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells. Tissue Antigens. 2009;74:277-289
    • (2009) Tissue Antigens , vol.74 , pp. 277-289
    • Berry, L.J.1    Moeller, M.2    Darcy, P.K.3
  • 17
    • 33846215917 scopus 로고    scopus 로고
    • Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors
    • Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109:170-179
    • (2007) Cancer , vol.109 , pp. 170-179
    • Beckman, R.A.1    Weiner, L.M.2    Davis, H.M.3
  • 18
    • 0035987985 scopus 로고    scopus 로고
    • Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients
    • Schule J, Bergkvist L, Hakansson L, et al. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat. 2002;74:33-40
    • (2002) Breast Cancer Res Treat , vol.74 , pp. 33-40
    • Schule, J.1    Bergkvist, L.2    Hakansson, L.3
  • 19
    • 0036307836 scopus 로고    scopus 로고
    • Clinical significance of poor CD3 response in head and neck cancer
    • Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res. 2002;8:745-751
    • (2002) Clin Cancer Res , vol.8 , pp. 745-751
    • Shibuya, T.Y.1    Nugyen, N.2    McLaren, C.E.3
  • 20
    • 2342655822 scopus 로고    scopus 로고
    • Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes
    • Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9:577-586
    • (2004) Mol Ther , vol.9 , pp. 577-586
    • Wang, J.1    Press, O.W.2    Lindgren, C.G.3
  • 21
    • 12344276425 scopus 로고    scopus 로고
    • Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor
    • Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res. 2005;29:301-306
    • (2005) Leuk Res , vol.29 , pp. 301-306
    • Schirrmann, T.1    Pecher, G.2
  • 22
    • 0035576250 scopus 로고    scopus 로고
    • Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule
    • Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167:6123-6131
    • (2001) J Immunol , vol.167 , pp. 6123-6131
    • Hombach, A.1    Wieczarkowiecz, A.2    Marquardt, T.3
  • 23
    • 84906086053 scopus 로고    scopus 로고
    • Construction of fusion gene anti-erbB2-scFv-Fc-CD28-CD3 (z) and expression in eukaryotic cell
    • Sui W, Su S, Hu W, et al. Construction of fusion gene anti-erbB2-scFv-Fc-CD28-CD3 (z) and expression in eukaryotic cell. Chin J Cell Biol. 2010;32:1-7
    • (2010) Chin J Cell Biol , vol.32 , pp. 1-7
    • Sui, W.1    Su, S.2    Hu, W.3
  • 24
    • 77951684508 scopus 로고    scopus 로고
    • Shaping successful and unsuccessful CD8 T cell responses following infection
    • Cox MA, Zajac AJ. Shaping successful and unsuccessful CD8 T cell responses following infection. J Biomed Biotechnol. 2010;159152:12
    • (2010) J Biomed Biotechnol , vol.12 , pp. 159152
    • Cox, M.A.1    Zajac, A.J.2
  • 25
    • 10744225529 scopus 로고    scopus 로고
    • Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor
    • Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 2004;64:1490-1495
    • (2004) Cancer Res , vol.64 , pp. 1490-1495
    • Gyobu, H.1    Tsuji, T.2    Suzuki, Y.3
  • 26
    • 27644445691 scopus 로고    scopus 로고
    • Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection
    • Moeller M, Haynes NM, Kershaw MH, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood. 2005; 106:2995-3003
    • (2005) Blood , vol.106 , pp. 2995-3003
    • Moeller, M.1    Haynes, N.M.2    Kershaw, M.H.3
  • 27
    • 0037456367 scopus 로고    scopus 로고
    • CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
    • Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856
    • (2003) Nature , vol.421 , pp. 852-856
    • Janssen, E.M.1    Lemmens, E.E.2    Wolfe, T.3
  • 28
    • 33645451483 scopus 로고    scopus 로고
    • Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
    • Baum C, Kustikova O, Modlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17:253-263
    • (2006) Hum Gene Ther , vol.17 , pp. 253-263
    • Baum, C.1    Kustikova, O.2    Modlich, U.3
  • 29
    • 33646887376 scopus 로고    scopus 로고
    • Genotoxicity of retroviral integration in hematopoietic cells
    • Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031-1049
    • (2006) Mol Ther , vol.13 , pp. 1031-1049
    • Nienhuis, A.W.1    Dunbar, C.E.2    Sorrentino, B.P.3
  • 30
    • 75449087525 scopus 로고    scopus 로고
    • Electro-mediated gene transfer and expression are controlled by the life-Time of DNA/ membrane complex formation
    • Faurie C, Rebersek M, Golzio M, et al. Electro-mediated gene transfer and expression are controlled by the life-Time of DNA/ membrane complex formation. J Gene Med. 2010;12:117-125
    • (2010) J Gene Med , vol.12 , pp. 117-125
    • Faurie, C.1    Rebersek, M.2    Golzio, M.3
  • 31
    • 77649160212 scopus 로고    scopus 로고
    • Comparative transfection of DNA into primary and transformed mammalian cells from different lineages
    • Maurisse R, De Semir D, Emamekhoo H, et al. Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol. 2010;10:9-17
    • (2010) BMC Biotechnol , vol.10 , pp. 9-17
    • Maurisse, R.1    De Semir, D.2    Emamekhoo, H.3
  • 32
    • 84934439329 scopus 로고    scopus 로고
    • Electroporation-based gene therapy: Recent evolution in the mechanism description and technology developments
    • Mir LM. Electroporation-based gene therapy: Recent evolution in the mechanism description and technology developments. Methods Mol Biol. 2014;1121:3-23
    • (2014) Methods Mol Biol , vol.1121 , pp. 3-23
    • Mir, L.M.1
  • 33
    • 84934443007 scopus 로고    scopus 로고
    • Electroporation formulation for cell therapy
    • Hu J, Li S. Electroporation formulation for cell therapy. Methods Mol Biol. 2014;1121:55-60
    • (2014) Methods Mol Biol , vol.1121 , pp. 55-60
    • Hu, J.1    Li, S.2
  • 34
    • 33646398347 scopus 로고    scopus 로고
    • Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma
    • Cooper LJ, Ausubel L, Gutierrez M, et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy. 2006;8:105-117
    • (2006) Cytotherapy , vol.8 , pp. 105-117
    • Cooper, L.J.1    Ausubel, L.2    Gutierrez, M.3
  • 35
    • 34548485103 scopus 로고    scopus 로고
    • Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
    • Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18:712-725
    • (2007) Hum Gene Ther , vol.18 , pp. 712-725
    • Wang, J.1    Jensen, M.2    Lin, Y.3
  • 36
    • 58149477054 scopus 로고    scopus 로고
    • Effect of trehalose on protein structure
    • Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci. 2009;18:24-36
    • (2009) Protein Sci , vol.18 , pp. 24-36
    • Jain, N.K.1    Roy, I.2
  • 37
    • 77950853704 scopus 로고    scopus 로고
    • Activation of caspases and apoptosis in response to low-voltage electric pulses
    • Matsuki N, Takeda M, Ishikawa T, et al. Activation of caspases and apoptosis in response to low-voltage electric pulses. Oncol Rep. 2010;23:1425-1433
    • (2010) Oncol Rep , vol.23 , pp. 1425-1433
    • Matsuki, N.1    Takeda, M.2    Ishikawa, T.3
  • 38
    • 38349177530 scopus 로고    scopus 로고
    • Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy
    • Meehan KR, Wu J, Webber SM, et al. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy. 2008;10:30-37
    • (2008) Cytotherapy , vol.10 , pp. 30-37
    • Meehan, K.R.1    Wu, J.2    Webber, S.M.3
  • 39
    • 0033655529 scopus 로고    scopus 로고
    • Human T lymphocyte genetic modification with naked DNA
    • Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1: 49-55
    • (2000) Mol Ther , vol.1 , pp. 49-55
    • Jensen, M.C.1    Clarke, P.2    Tan, G.3
  • 40
    • 18544408628 scopus 로고    scopus 로고
    • A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase i trial
    • Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res. 2000;6:3081-3087
    • (2000) Clin Cancer Res , vol.6 , pp. 3081-3087
    • Alvarez, R.D.1    Barnes, M.N.2    Gomez-Navarro, J.3
  • 41
    • 33745070631 scopus 로고    scopus 로고
    • Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes
    • Clemenceau B, Congy-Jolivet N, Gallot G, et al. Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107:4669-4677
    • (2006) Blood , vol.107 , pp. 4669-4677
    • Clemenceau, B.1    Congy-Jolivet, N.2    Gallot, G.3
  • 42
    • 0036196127 scopus 로고    scopus 로고
    • Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv
    • Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002;9:256-262
    • (2002) Gene Ther , vol.9 , pp. 256-262
    • Arafat, W.O.1    Gomez-Navarro, J.2    Buchsbaum, D.J.3
  • 43
    • 0041308272 scopus 로고    scopus 로고
    • Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma
    • Barker SD, Dmitriev IP, Nettelbeck DM, et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther. 2003;10:1198-1204
    • (2003) Gene Ther , vol.10 , pp. 1198-1204
    • Barker, S.D.1    Dmitriev, I.P.2    Nettelbeck, D.M.3
  • 44
    • 16644364683 scopus 로고    scopus 로고
    • Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene
    • Guo MG, Jiang MH, Yang Q, et al. Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene. Zhonghua Yi Xue Za Zhi. 2004;84:1147-1151
    • (2004) Zhonghua Yi Xue Za Zhi , vol.84 , pp. 1147-1151
    • Guo, M.G.1    Jiang, M.H.2    Yang, Q.3
  • 45
    • 33745818353 scopus 로고    scopus 로고
    • High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules
    • Shen YC, Wang XH, Wang XM, et al. High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules. World J Gastroenterol. 2006;12:3859-3865
    • (2006) World J Gastroenterol , vol.12 , pp. 3859-3865
    • Shen, Y.C.1    Wang, X.H.2    Wang, X.M.3
  • 46
    • 32544449156 scopus 로고    scopus 로고
    • Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli
    • Ming-Kai X, Cheng-Gang Z. Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli. Appl Microbiol Biotechnol. 2006;70:78-84
    • (2006) Appl Microbiol Biotechnol , vol.70 , pp. 78-84
    • Ming-Kai, X.1    Cheng-Gang, Z.2
  • 47
    • 32544431927 scopus 로고    scopus 로고
    • Specific delivery of corroles to cells via noncovalent conjugates with viral proteins
    • Agadjanian H, Weaver JJ, Mahammed A, et al. Specific delivery of corroles to cells via noncovalent conjugates with viral proteins. Pharm Res. 2006;23:367-377
    • (2006) Pharm Res , vol.23 , pp. 367-377
    • Agadjanian, H.1    Weaver, J.J.2    Mahammed, A.3
  • 48
    • 49149106425 scopus 로고    scopus 로고
    • Barnase as a new therapeutic agent triggering apoptosis in human cancer cells
    • Edelweiss E, Balandin TG, Ivanova JL, et al. Barnase as a new therapeutic agent triggering apoptosis in human cancer cells. PLoS One. 2008;3:e2434
    • (2008) PLoS One , vol.3
    • Edelweiss, E.1    Balandin, T.G.2    Ivanova, J.L.3
  • 49
    • 11144238604 scopus 로고    scopus 로고
    • Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
    • Shahied LS, Tang Y, Alpaugh RK, et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279:53907-53914
    • (2004) J Biol Chem , vol.279 , pp. 53907-53914
    • Shahied, L.S.1    Tang, Y.2    Alpaugh, R.K.3
  • 50
    • 25844517682 scopus 로고    scopus 로고
    • Phase i clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
    • von Minckwitz G, Harder S, Hovelmann S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005;7: R617-R626
    • (2005) Breast Cancer Res , vol.7
    • Von Minckwitz, G.1    Harder, S.2    Hovelmann, S.3
  • 51
    • 0035135433 scopus 로고    scopus 로고
    • Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
    • Marshall KW, Marks JD. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001;24:27-36
    • (2001) J Immunother , vol.24 , pp. 27-36
    • Marshall, K.W.1    Marks, J.D.2
  • 52
    • 13844296952 scopus 로고    scopus 로고
    • A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2
    • Biburger M, Weth R, Wels WS. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. J Mol Biol. 2005;346:1299-1311
    • (2005) J Mol Biol , vol.346 , pp. 1299-1311
    • Biburger, M.1    Weth, R.2    Wels, W.S.3
  • 53
    • 0037441593 scopus 로고    scopus 로고
    • T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect
    • Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood. 2003;101: 1637-1644
    • (2003) Blood , vol.101 , pp. 1637-1644
    • Cooper, L.J.1    Topp, M.S.2    Serrano, L.M.3
  • 54
    • 0038246383 scopus 로고    scopus 로고
    • Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy
    • Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 2003;5:131-138
    • (2003) Cytotherapy , vol.5 , pp. 131-138
    • Jensen, M.C.1    Cooper, L.J.2    Wu, A.M.3
  • 55
    • 47649130059 scopus 로고    scopus 로고
    • Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene
    • Yu K, Hu Y, Tan Y, et al. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma. 2008;49:1368-1373
    • (2008) Leuk Lymphoma , vol.49 , pp. 1368-1373
    • Yu, K.1    Hu, Y.2    Tan, Y.3
  • 56
    • 50549096284 scopus 로고    scopus 로고
    • Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    • Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261-2271
    • (2008) Blood , vol.112 , pp. 2261-2271
    • Till, B.G.1    Jensen, M.C.2    Wang, J.3
  • 57
    • 0036137615 scopus 로고    scopus 로고
    • Human T-lymphocyte cytotoxicity and proliferation Directed by a single chimeric TCRzeta/CD28 receptor
    • Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation Directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20:70-75
    • (2002) Nat Biotechnol , vol.20 , pp. 70-75
    • Maher, J.1    Brentjens, R.J.2    Gunset, G.3
  • 58
    • 0037454757 scopus 로고    scopus 로고
    • Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain
    • Losch FO, Muller R, Mutschler B, et al. Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain. Int J Cancer. 2003;103: 399-407
    • (2003) Int J Cancer , vol.103 , pp. 399-407
    • Losch, F.O.1    Muller, R.2    Mutschler, B.3
  • 59
    • 0033692892 scopus 로고    scopus 로고
    • Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions
    • Patel SD, Ge Y, Moskalenko M, et al. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother. 2000;23:661-668
    • (2000) J Immunother , vol.23 , pp. 661-668
    • Patel, S.D.1    Ge, Y.2    Moskalenko, M.3
  • 60
    • 69249248185 scopus 로고    scopus 로고
    • Genetically engineered T cells to target EGFRvIII expressing glioblastoma
    • Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009;94:373-382
    • (2009) J Neurooncol , vol.94 , pp. 373-382
    • Bullain, S.S.1    Sahin, A.2    Szentirmai, O.3
  • 61
    • 0036047663 scopus 로고    scopus 로고
    • Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis
    • Ren-Heidenreich L, Mordini R, Hayman GT, et al. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother. 2002;51:417-423
    • (2002) Cancer Immunol Immunother , vol.51 , pp. 417-423
    • Ren-Heidenreich, L.1    Mordini, R.2    Hayman, G.T.3
  • 62
    • 0031927364 scopus 로고    scopus 로고
    • Crossregulation between Th1 and Th2 cells
    • Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol. 1998;18:275-303
    • (1998) Crit Rev Immunol , vol.18 , pp. 275-303
    • Morel, P.A.1    Oriss, T.B.2
  • 63
    • 0030022782 scopus 로고    scopus 로고
    • Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the longterm survival of memory cells
    • Mueller DL, Seiffert S, Fang W, et al. Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the longterm survival of memory cells. J Immunol. 1996;156: 1764-1771
    • (1996) J Immunol , vol.156 , pp. 1764-1771
    • Mueller, D.L.1    Seiffert, S.2    Fang, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.